Skip to main content

Table 2 Comparison of clinical characteristics at baseline

From: Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept

Characteristic

Responder

Nonresponder

P value

Age (years)

48.33 (± 12.29)

58.14 (± 13.67)

0.125a

Gender (male)

2/12

2/7

0.603b

Rheumatoid arthritis duration (years)

13.5 (± 10.46)

18.86 (± 13.93)

0.353a

Steroids (mg/d)

6.71 (± 5.16)

10.43 (± 6.80)

0.195a

28-joint-count Disease Activity Score baseline

5.75 (± 0.94)

5.33 (± 0.97)

0.364a

Antibodies to cyclic citrullinated peptide-negative

5/12

1/7

0.333b

Disease-modifying antirheumatic drugs

   

   None

3/12

4/7

0.326b

   Leflunomide

2/12

2/7

0.603b

   Methotrexate

5/12

1/7

0.333b

   Cyclosporin A

1/12

0/7

1.000b

   Sulfasalazine/hydroxychloroquin

1/12

0/7

1.000b

  1. Both patient groups show similar characteristics before therapy onset (mean ± standard deviation and number of patients, respectively). Statistical tests (atwo-sample t test, bexact Fisher test) were applied to check whether any of the parameters are associated with clinical outcome.